Jump to content

Pegfilgrastim

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Srich32977 (talk | contribs) at 01:28, 18 October 2016 (Fixed typo). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pegfilgrastim
Clinical data
Trade namesoriginally Neulasta, other brand names worldwide[1]
AHFS/Drugs.comMonograph
MedlinePlusa607058
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life15–80 hrs
Identifiers
  • N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard100.169.155 Edit this at Wikidata
Chemical and physical data
FormulaC845H1343N223O243S9 + PEG
Molar mass39,000 g/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[2]

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[4][3]

In the United States as of 2015 the branded form costs between $5,327 and $8,191 USD a dose.[5]

Biosimilars

In July 2016 the US FDA rejected a biosimilar application from Sandoz.[6]

In 2016 Coherus BioSciences is running clinical studies on its own pegfilgrastim biosimilar CHS-1701.[6]

References

  1. ^ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
  2. ^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.
  3. ^ a b Drugs.com: Pegfilgrastim
  4. ^ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, pp. 139, 158.
  5. ^ Langreth, Robert (June 29, 2016). "Decoding Big Pharma's Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016.
  6. ^ a b US FDA rejects Sandoz’s Neulasta biosimilar. 19 July 2016